Haloperidol Arena (Haloperidol)

Haloperidol Arena is prescribed for several psychiatric and neurological conditions where dopamine blockade is therapeutic.

• Schizophrenia (including maintenance therapy).
• Acute psychotic episodes associated with mood disorders or substance use.
• Tourette syndrome with prominent motor or vocal tics.
• Severe agitation or aggression in hospitalized patients.
• Short‑term control of psychosis in patients unable to tolerate other antipsychotics.
• Management of psychotic symptoms in patients with comorbid neurological disorders such as Huntington’s disease.
• Adjunctive therapy for refractory aggression in dementia when other options are insufficient.

Haloperidol Arena may produce a range of adverse effects that reflect its activity at dopamine, histamine, adrenergic, and muscarinic receptors.

Common

• Drowsiness or sedation, which may affect alertness and driving ability.
• Dry mouth, often leading to increased thirst or difficulty swallowing.
• Constipation, potentially requiring dietary fiber or laxatives.
• Extrapyramidal symptoms such as mild tremor, rigidity, or restlessness (akathisia).
• Weight gain or increased appetite, which can contribute to metabolic changes.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by high fever, muscle rigidity, autonomic instability, and altered mental status.
• Tardive dyskinesia, a potentially irreversible movement disorder presenting as repetitive, involuntary facial or limb movements after long‑term therapy.
• Severe orthostatic hypotension, causing sudden drops in blood pressure upon standing and possible fainting.

When prescribing Haloperidol Arena, clinicians consider several precautionary factors to minimize risk and ensure safe use.

• Assess for a history of cardiovascular disease, as haloperidol can affect heart rhythm.
• Evaluate for prior extrapyramidal reactions or movement disorders.
• Use caution in patients with hepatic or renal impairment because metabolism may be altered.
• Monitor elderly patients closely, especially those with dementia, due to increased sensitivity to sedation and falls.
• Consider pregnancy and breastfeeding status; data are limited, so benefits must outweigh potential risks.
• Review concomitant medications that may prolong QT interval.

Haloperidol Arena can interact with other medicines that influence its metabolism or additive pharmacologic effects.

Avoid

• Other antipsychotics or dopamine antagonists, which may increase risk of extrapyramidal symptoms.
• Medications that markedly prolong the QT interval, such as certain antiarrhythmics or fluoroquinolones.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.

Use with caution

• CYP2D6 substrates (e.g., metoprolol, codeine) because haloperidol may affect their metabolism.
• CNS depressants including benzodiazepines, opioids, or alcohol, which can enhance sedation.
• Antihypertensive agents, as orthostatic hypotension may be potentiated.